A decreased activity of FGF-23 due to SLC34A1 mutation and subsequent hyperphosphaturia and hypophosphatemia, indirectly stimulate synthesis of 1,25(OH)2D that may produce hypercalcemia, hypercalciuria and nephrocalcinosis (133). Here, FGF23 is linked to hypercalcemia disease.